Introduction {#s1}
============

Prompt detection of tuberculosis (TB) infection is vital for TB control [@pone.0001335-Keeler1]. The development of commercial interferon-gamma (IFN-γ) release assays (IGRA) has focussed attention on the use of host immune reactivity as a marker of infection. Increasing data suggest that blood-based IGRA have significant advantages when investigating latent TB infection (LTBI) compared to the much older immunoassay the tuberculin skin test (TST) [@pone.0001335-Brock1], [@pone.0001335-Ewer1], [@pone.0001335-Rangaka1], [@pone.0001335-Menzies1]. However, both the TST and IGRA are much less helpful in the diagnosis of active TB, especially when this is accompanied by immune suppression such as HIV [@pone.0001335-Dewan1], [@pone.0001335-Mazurek1], [@pone.0001335-Liebeschuetz1].

Distinct TB antigen-specific responses are found in the lung [@pone.0001335-Schwander1], [@pone.0001335-Schwander2]. Given that TB infection is transmitted typically by inhalation, it is likely that these responses, which are typically of a much higher frequency than found in blood, may be of greater importance than the immunological findings within peripheral blood. Clinical studies using bronchoscopy and broncho-alveolar lavage (BAL) to recover lung cells have confirmed that the pulmonary T-lymphocyte immune response can be used with excellent sensitivity to detect active TB, including non-pulmonary and HIV-related forms [@pone.0001335-Barry1], [@pone.0001335-Breen1]. These early data have been confirmed in larger studies of spontaneous sputum-smear negative cases. [@pone.0001335-Jafari1], [@pone.0001335-Breen2].

Not only is a lung-based approach an exciting advance in TB immune-diagnostics; but also it allows direct smear and culture to be performed on the same primary sample. Given persisting high global rates of drug resistance and the emergence of XDR-TB, the facility to run such immunology and microbiology tests on a single sample is of great potential significance [@pone.0001335-Raviglione1].

Obtaining lung fluid by bronchoscopy and BAL is both expensive and invasive [@pone.0001335-McWilliams1]. Recently a number of studies have shown that non-invasive sputum induction (SI) using inhaled hypertonic saline for TB diagnosis has a similar microbiological yield to BAL-yet at a substantially reduced cost, and in a significantly more patient-friendly manner [@pone.0001335-Conde1], [@pone.0001335-Brown1]. However, cell populations obtained by the two methods differ, which may limit assessment of TB antigen-specific responses when using SI [@pone.0001335-Fireman1].

In this study we have investigated for the first time whether a single sample obtained by simple SI methodology can be used to diagnose TB promptly using immunological assays (flow cytometry and ELISpot) in combination with traditional microbiological techniques.

Methods {#s2}
=======

Subjects {#s2a}
--------

The study was approved by the Royal Free Hospital Ethics Committee (LREC 6236). Adults being investigated for TB who were either (1) sputum acid-fast bacilli (AFB) smear-negative, or (2) not producing sputum and had no positive AFB smears from non-pulmonary samples, were recruited from our urban Teaching Hospital between April 2005 and April 2006. Written informed consent was obtained. Subjects continued to be investigated by their physician independently of SI where appropriate. No subject had commenced anti-tuberculosis medication at the time of study.

SI was performed in a portable, negative-pressure isolation chamber (Elwyn Roberts, Shropshire, UK) using 3% saline delivered via an ultrasonic nebuliser (Sunrise Medical, Wollaston, UK) for 20 minutes. Peak expiratory flow rate (PEFR) was measured every 5 minutes and induction terminated if PEFR declined by \>15%, or if chest discomfort were reported. Prior to induction subjects were asked to clear their mouth and nose of any residual saliva or secretions. After each five minute period and prior to any expectoration of sputum this process was repeated. Sputum was expectorated without assistance in to a sterile container.

Sample handling and laboratory investigation {#s2b}
--------------------------------------------

Sputum was processed within 2 hours. An equivalent volume of 0.1% dithiothreitol solution (Sigma, UK) was added, the sample rolled for 20 minutes at room temperature and an aliquot (usually 50% of the total sample) removed for microbiological investigation.

Flow cytometry {#s2c}
--------------

Absolute leucocyte, lymphocyte and CD4+ T-cell numbers were determined by flow cytometry [@pone.0001335-Barry2]. Detection of IFN-γ synthesis following 16 hour (overnight) incubation was performed as previously described [@pone.0001335-Barry1]. In brief, 5×10^4^ CD4 lymphocytes were incubated with tissue culture medium (TCM) alone {negative control}; TCM with PPD (Mycos Research, CO, USA) or TCM with PHA (Sigma) {positive control}. Brefeldin A (Sigma) was added after 2 hours. Harvested cells were fixed and permeabilised, and stained for expression of CD3, CD4 and IFN-γ. Lymphocytes, identified by scatter, were gated according to CD3 expression to produce a histogram of IFN-γ producing CD4+ and CD4- T cells. The IFN-γ+ CD4+ lymphocyte frequency as a percentage of the total CD4+ T-lymphocyte population (%CD4+IFN-γ+) was determined. The %CD4+IFN-γ+ in the negative control was subtracted from that in the PPD-stimulated sample to give a percentage value of PPD-specific CD4+ IFN-γ+ lymphocytes (%PPD-specific CD4+IFN-γ+). No samples were excluded due to high negative control responses which had a median %CD4+IFN-γ+ value of 1.04%. This did not differ significantly between subjects with and without active TB (1.04% versus 0.83% respectively). Using data from early experiments an adequate positive control response was taken as a CD3+ IFN-γ+ response of \>10% (median \[range\] positive control response was 49.3% \[16.0--78.3\]). All flow cytometry and evaluation of %PPD-specific CD4+IFN-γ+ responses was performed by RAMB.

ELISpot {#s2d}
-------

ELISpot assays were also performed on induced sputum samples as described previously [@pone.0001335-Lalvani1]. Briefly 1×10^5^ leukocytes per well were cultured overnight with duplicates of TCM alone \[negative control\], PPD or PHA \[positive control\] in 96 well anti-IFN-γ (Mabtech, Stockholm, Sweden) coated PVDF-backed plates (Millipore, Watford, UK). After overnight incubation IFN-γ spot-forming cells (SFC) were detected according to the manufacturer\'s instructions (Mabtech). The mean of duplicate conditions was calculated. Results are presented as background subtracted (delta) spot-forming units (ΔSFU) per/10^6^ cells. A negative response to the positive control, PHA, was used to determine assay failure, in which case the result was discounted from the data set. Since none of the PHA treated cells produced a negative result, no assays were excluded. All ELISpot assays and determination of these results were performed by GADH.

Microbiology {#s2e}
------------

Microscopy acid-fast bacilli (AFB) smears were prepared and stained with auramine-O; and positive smears were confirmed using a Ziehl-Neelsen stain. All positive cultures for *Mycobacterium tuberculosis (M.tb)* were confirmed by the Mycobacterial Reference Laboratory, London, UK.

Diagnostic definition {#s2f}
---------------------

Clinical diagnostic decisions were made without reference to immunological data. A final diagnosis of "active TB" was accepted when (1) *M.tb* was cultured or (2) there was clear evidence for a clinical diagnosis based on radiology or histology with an appropriate response to treatment. A final diagnosis of "quiescent or latent TB" was accepted if there were a clearly recorded history of exposure to a smear positive index case with supporting tuberculin skin test (TST) or radiological results but the clinical decision had been made not to commence full anti-tuberculosis therapy. A final diagnosis of "not TB" was accepted if an alternative diagnosis were reached, symptoms resolved rapidly and anti-tuberculosis therapy was not commenced. All subjects without culture-confirmed TB have been followed up for at least 12 months for changes in their diagnostic categorisation.

Statistical assessment {#s2g}
----------------------

Comparisons between groups were made using the Wilcoxon test. The data were analysed using SAS version 8.2 (SAS Institute Inc, Cary, NC).

Results {#s3}
=======

Patient information {#s3a}
-------------------

Forty-two individuals underwent sputum induction. Median age \[range\] was 32 years \[21--63\]. Ethnic background was Black 36% (15 of 42), Asian 33% (14 of 42), Caucasian 31% (13 of 42). 90% (38) had received Bacille-Calmette-Guerin (BCG) vaccination. 38% (16 of 42) were HIV-infected with a median \[range\] blood CD4 count of 332 cells/µl \[103--748\]. The subjects are described individually in [Table 1](#pone-0001335-t001){ref-type="table"}.

10.1371/journal.pone.0001335.t001

###### Description of 42 sputum smear-negative or sputum non-producing subjects undergoing sputum induction for the investigation of possible tuberculosis (subjects are categorised by final diagnoses of active TB; quiescent or latent TB; and not TB, and percentage value of PPD-specific CD4+ IFN-γ+ lymphocytes \[%PPD-specific CD4+IFN-γ+\])

![](pone.0001335.t001){#pone-0001335-t001-1}

  Country of origin            Age   BCG+   HIV+   Blood CD4 count (cells/ul)                                     Final diagnosis                                     AFB smear of IS   IS culture for *Mtb*   %PPD-specific CD4+ IFN-γ+
  --------------------------- ----- ------ ------ ---------------------------- ------------------------------------------------------------------------------------- ----------------- ---------------------- ---------------------------
  Angola                       34    Yes    Yes               350                                         Culture-confirmed Pulmonary TB                                 Negative             Positive                    0%
  Egypt                        29    Yes     No                na                                        Culture-confirmed Cervical LN TB                                Negative             Negative                    0%
  Pakistan                     25    Yes     No                na                     Culture-confirmed Testicular and pulmonary TB (no respiratory symptoms)            Positive             Positive                   0.13%
  Ghana                        32    Yes    Yes               350                                         Culture-confirmed Pulmonary TB                                 Negative             Positive                   0.67%
  Bangladesh                   25    Yes     No                na                            Culture-confirmed Cervical and pulmonary TB (normal CXR)                    Negative             Positive                   0.67%
  Vietnam                      32     No     No                na                                        Culture-confirmed Cervical LN TB                                Negative             Negative                   0.92%
  India                        21    Yes     No                na                                        Culture-confirmed Cervical LN TB                                Negative             Negative                   1.09%
  India                        29    Yes     No                na                                            Presumptive Pulmonary TB                                    Negative             Negative                   1.14%
  Somalia                      21    Yes     No                na                                         Culture-confirmed Pulmonary TB                                 Negative             Positive                   1.33%
  Somalia                      32    Yes     No                na                                            Presumptive Abdominal TB                                    Negative             Negative                   1.44%
  Iran                         34    Yes     No                na                                         Culture-confirmed Pulmonary TB                                 Negative             Positive                   1.81%
  Somalia                      21     No     No                na                            Culture-confirmed Cervical and pulmonary TB (normal CXR)                    Negative             Positive                   2.09%
  Brazil                       31    Yes    Yes               748                                       Culture-confirmed Mediastinal LN TB                              Negative             Negative                   2.29%
  England                      29    Yes     No                na                                         Culture-confirmed Pulmonary TB                                 Negative             Positive                   2.77%
  South Africa                 32    Yes    Yes               219                                            Presumptive Pulmonary TB                                    Negative             Negative                   2.96%
  Pakistan                     24    Yes     No                na                                         Culture-confirmed Pulmonary TB                                 Negative             Negative                   3.62%
  Zimbabwe                     54    Yes     No                na                                           Presumptive Pericardial TB                                   Negative             Negative                   3.75%
  Pakistan                     31    Yes     No                na                                  Presumptive Cervical LN TB + erythema nodosum                         Negative             Negative                   4.17%
  Zimbabwe                     53     No    Yes               612                                   Presumptive Mediastinal and abdominal LN TB                          Negative             Negative                   4.49%
  Ireland                      36    Yes    Yes               493                                          Culture-confirmed Pleural TB                                  Negative             Negative                   4.72%
  Nepal                        27    Yes     No                na                                          Presumptive Mediastinal LN TB                                 Negative             Negative                   6.98%
  Wales                        63    Yes    Yes               408                                         Culture-confirmed Pulmonary TB                                 Positive             Positive                   7.76%
  England                      55    Yes     No                na                                         Culture-confirmed Pulmonary TB                                 Negative             Positive                   8.85%
  England (Indian descent)     21    Yes     No                na                                       Culture-confirmed Mediastinal LN TB                              Negative             Negative                   9.94%
  Gambia                       23     No     No                na                                         Culture-confirmed Pulmonary TB                                 Positive             Positive                  15.93%
  Bulgaria                     33    Yes     No                na                                         Culture-confirmed Pulmonary TB                                 Positive             Positive                  16.27%
  India                        28    Yes     No                na                                        Culture-confirmed Cervical LN TB                                Negative             Negative                  23.93%
  England                      61    Yes     No                na               Quiescent/latent TB (TST +. Previous contact of smear+ TB. Concurrent brain tumour)      Negative             Negative                   0.72%
  Ireland                      31    Yes    Yes               459                       Quiescent/latent TB (Recent contact of smear+ TB. IDU. Scar on CXR)              Negative             Negative                   1.94%
  Nigeria                      30    Yes    Yes               205                                Quiescent/latent TB (Recent contact of smear+ TB)                       Negative             Negative                   2.10%
  DRC                          29    Yes    Yes               103                                            Cough of uncertain cause                                    Negative             Negative                    0%
  England (African descent)    30    Yes     No                na                                                   Sarcoidosis                                          Negative             Negative                    0%
  India                        46    Yes     No                na                                                      LRTI                                              Negative             Negative                    0%
  South Africa                 27    Yes     No                na                                                      LRTI                                              Negative             Negative                   0.06%
  Pakistan                     32    Yes     No                na                                                      LRTI                                              Negative             Negative                    0%
  Spain                        34    Yes    Yes               332                           Fever of uncertain cause. Resolved with anti-HIV treatment                   Negative             Negative                   0.12%
  Zimbabwe                     36    Yes    Yes               230                                                  Previous MAI                                          Negative             Negative                    0%
  England                      34    Yes    Yes               303                                                      LRTI                                              Negative             Negative                    0%
  China                        35    Yes    Yes               313                                                      LRTI                                              Negative             Negative                    0%
  Nigeria                      53    Yes    Yes               102                              Multiple Enlarged LNs. Resolved with anti-HIV therapy                     Negative             Negative                    0%
  Zimbabwe                     39    Yes    Yes               150                            SLE with cough and fever. Resolved with immunosuppression                   Negative             Negative                   0.11%
  India                        31    Yes     No                na                                                      LRTI                                              Negative             Negative                    0%

[Abbreviations]{.ul}: AFB = acid-fast bacilli; BCG+ = Bacille-Calmette-Guerin vaccinated; CXR = chest radiograph; DRC = Democratic Republic of Congo; HIV+ = Human immunodeficiency virus positive; IDU = injecting drug user; IS = induced-sputum; LN = lymph node; LRTI = lower respiratory tract infection; Mtb = Mycobacterium tuberculosis; na = not applicable; ND = not done; SLE = systemic lupus erythematosis; TST = tuberculin skin test; TB = tuberculosis

Active TB was diagnosed in 27 subjects of whom 26% (7 of 27) were HIV-infected. 74% (20 of 27) were *M.tb* culture-positive. 56% (15 of 27) had pulmonary and 44% (12 of 27) had active TB diagnosed at a non-pulmonary site.

Three of 42 subjects received a final diagnosis of quiescent or latent TB. A final diagnosis of "not TB" was made in 12 subjects, all of whom had been previously BCG-vaccinated and 7 of 12 (58%) were HIV-infected. These data are shown in [Table 2](#pone-0001335-t002){ref-type="table"}.

10.1371/journal.pone.0001335.t002

###### Immunoassay and microbiology results alone and in combination compared to final diagnosis.
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                                                   Active TB n = 27   Latent/quiescent TB n = 3   Not TB n = 12   *Active pulmonary TB n = 15*   *Active non-pulmonary TB n = 12*
  ----------------------------------------------- ------------------ --------------------------- --------------- ------------------------------ ----------------------------------
  **HIV+**                                             7 (26%)                 2 (67%)               7 (58%)                4 (27%)                          3 (25%)
  **BCG+**                                             23 (85%)               3 (100%)              12 (100%)               13 (87%)                         10 (83%)
  ***Mtb*** **culture+ from any site**                 20 (74%)                0 (0%)                0 (0%)                 13 (87%)                         7 (58%)
  ***Mtb*** **culture+ from IS**                       13 (48%)                0 (0%)                0 (0%)                 13 (87%)                          0 (0%)
  **AFB smear+ from IS**                               4 (15%)                 0 (0%)                0 (0%)                 4 (27%)                           0 (0%)
  **Immunoassay+**                                     24 (89%)               3 (100%)               0 (0%)                 13 (87%)                         11 (92%)
  **AFB smear or immunoassay+**                        25 (93%)               3 (100%)               0 (0%)                 14 (93%)                         11 (92%)
  **IS** ***Mtb*** **culture+ or immunoassay+**        26 (96%)               3 (100%)               0 (0%)                15 (100%)                         11 (92%)

Subjects diagnosed with active TB are further divided according to whether this was pulmonary or non-pulmonary (italics)

[Abbreviations]{.ul}: AFB = acid-fast bacilli; BCG+ = Bacille-Calmette-Guerin vaccinated; HIV+ = HIV-infected; IS = induced-sputum; Mtb = Mycobacterium tuberculosis; TB = tuberculosis

Induced-sputum cell yields and phenotypes {#s3b}
-----------------------------------------

No induction had to be terminated prematurely and no significant symptoms or reduction in PEFR were noted. The median time after starting induction at which sputum expectoration commenced was 10 minutes [@pone.0001335-Brock1]--[@pone.0001335-Barry2] and the median volume expectorated was 5 mls [@pone.0001335-Keeler1]--[@pone.0001335-Barry2]. The median absolute yield of CD45+ leucocytes was 6.6×10^6^ \[1.0--22.5\], the percentage of CD45+ leucocytes that were lymphocytes was 4.90% \[0.60--41.10%\] and the ratio of CD4+ to CD8+ lymphocytes was 1.88 \[0.15--29.99\].

PPD-specific IFN-γ response versus final diagnosis {#s3c}
--------------------------------------------------

In those for whom the final diagnosis was active TB the median \[range\] %PPD-specific CD4+IFN-γ+ was 2.77% \[0--23.93%\]. This was unaffected by HIV co-infection: 2.96% \[0--7.76%\] for HIV/TB versus 2.43% \[0--23.93%\] for TB alone (p = 0.87) ([Figure 1](#pone-0001335-g001){ref-type="fig"}). In subjects whose final diagnosis was not active TB, the median \[range\] %PPD-specific CD4+IFN-γ+ was 0% \[0--2.10%\] (p\<0.0001 versus active TB). Delineation of the non-active TB group on the basis of whether the final clinical diagnosis was quiescent/latent TB or not TB revealed %PPD-specific CD4+IFN-γ+ values of 1.94% \[0.72%--2.10%\] versus 0% \[0--0.12%\] respectively ([Figure 1](#pone-0001335-g001){ref-type="fig"}).

![A comparison of final diagnosis against %PPD-specific CD4+IFN-γ+ responses following overnight stimulation of induced-sputum in 42 spontaneous sputum smear negative subjects with possible tuberculosis (medians shown as horizontal bars).\
The suggested diagnostic cut-off of 0.5% is indicated by the hatched line.](pone.0001335.g001){#pone-0001335-g001}

Induced-sputum as a diagnostic tool--Immunoassay alone and in combination with AFB smear or TB culture {#s3d}
------------------------------------------------------------------------------------------------------

From ROC curve analysis (data not shown), a post-hoc %PPD-specific CD4+IFN-γ+ value of ≥0.5% was selected to define a positive assay. Using this, the assay had a sensitivity of 89% (positive in 24 of 27 of subjects diagnosed with active TB \[17 of 20 (85%) with culture-confirmed M.tb and 7 of 7 (100%) who received a presumptive diagnosis\]); and a specificity of 80% (negative result in 12 of 15 of subjects where active TB was discounted). All 12 subjects with a final diagnosis of "not TB" had a negative assay.

Amongst those subjects with a final diagnosis of active TB the same induced-sputum sample used for the immunoassay was AFB smear-positive in 15% (4 of 27) of cases; and *M.tb* culture-positive in 48% (13 of 27). It should be noted that culture-confirmation of *M.tb* was obtained in 87% (13 of 15) of pulmonary cases using a single induced-sputum, but only 13% (2 of 15) with spontaneously expectorated sputum in the same subjects. When results were combined using a strategy for prompt diagnosis of AFB smear followed, if negative, by the immunoassay, 93% (25 of 27) had a positive result (4 of 27 \[15%\] smear-positive and 21 of the remaining 23 \[91%\] immunoassay-positive). With a strategy of immunoassay and culture, 96% of subjects (26 of 27) were positive (13 \[48%\] culture-positive, 24 \[89%\] immunoassay positive and 13 \[48%\] positive by immunoassay alone). The results according to final clinical diagnosis and site of active TB are displayed in [Table 2](#pone-0001335-t002){ref-type="table"}.

Induced sputum flow cytometry versus ELISpot {#s3e}
--------------------------------------------

In 9 subjects the IFN-γ response to PPD was measured on the same sample using flow cytometry and ELISpot. In 6 of these the final diagnosis was active TB (3 with pulmonary disease). Equivalent results with both methods were found in all 9 subjects ([Table 3](#pone-0001335-t003){ref-type="table"}; [Figure 2](#pone-0001335-g002){ref-type="fig"}).

![Cytometric dot plots and ELISpot wells from a subject with active tuberculosis, demonstrating interferon (IFN)-γ synthesis in response to overnight incubation of induced-sputum with purified-protein derivative of *Mycobacterium tuberculosis* (PPD).\
Panel A: Proportion of CD4+ lymphocytes producing IFN-γ after incubation with no antigen (Ag) added. Panel B: Proportion of CD4+ lymphocytes producing IFN-γ after incubation with PPD. Panel C: ELISpot wells showing the IFN-γ T-cell response after incubation with no antigen added. Panel D: ELISpot wells showing the IFN-γ T-cell response after incubation with PPD.](pone.0001335.g002){#pone-0001335-g002}

10.1371/journal.pone.0001335.t003

###### Comparison of flow cytometry and ELISpot techniques in assessing PPD-specific interferon-gamma responses

![](pone.0001335.t003){#pone-0001335-t003-3}

  Final diagnosis                            Flow cytometry-%PPD-specific CD4+IFN-γ+   ELISpot-IFN-γ SFU/10^6^ cells
  ----------------------------------------- ----------------------------------------- -------------------------------
  Mediastinal and abdominal lymph node TB                     4.49%                                 725
  Mediastinal lymph node TB                                   6.98%                                1020
  Pulmonary TB                                                8.85%                                 725
  Pulmonary TB                                               15.93%                                 535
  Pulmonary TB                                               16.27%                                3405
  Cervical lymph node TB                                     23.93%                                4120
  Not TB                                                       0%                                    5
  Not TB                                                      0.06%                                 10
  Not TB                                                      0.12%                                  0

[Abbreviations]{.ul}: SFU = spot forming units; TB = tuberculosis;

Discussion {#s4}
==========

This is the first study to demonstrate that a single induced-sputum sample can be used for combined immunological and microbiological TB diagnosis. In 42 individuals (38% of whom were HIV-infected) who were either not spontaneously producing sputum or in whom this was AFB smear-negative, our immunoassay had a sensitivity of 89% (24 of 27 positive) and specificity of 80% compared to a final clinical diagnosis of active TB. Although somewhat smaller numbers, these results compare very well with those achieved in blood in HIV-uninfected subjects [@pone.0001335-Mazurek1], and ours reported previously using BAL in a similar population [@pone.0001335-Breen2].

Combining our lung-orientated immunological approach with traditional microbiology produced prompt identification (induced-sputum AFB smear or immunoassay-positive) in 93% of cases; and overall identification (induced-sputum TB culture or immunoassay positive) in 96% of those with active TB at any body site. It should be noted that of the 15 subjects with active pulmonary TB, 4 were AFB smear-positive and 13 were immunoassay-positive on a single induced sputum sample. Thus the latter greatly increased the chance of prompt diagnosis of active, infectious pulmonary TB. The induced sputum immunoassay was also unaffected by HIV status, TB disease site, and BCG vaccination. The similar results obtained using the different methodologies of flow cytometry and ELISpot also demonstrate that the potential of this sputum-based method is not limited to one technique.

Confounding positive responses from BCG-vaccinated individuals without TB have been observed using both the tuberculin skin test (TST) and PPD-based blood assays [@pone.0001335-Pai1]. This has led to the use of smaller antigens encoded in the region of difference 1 (RD1) portion of the genome of *M.tb,* which is absent in BCG-strains [@pone.0001335-Harboe1]. However, in our lung-based assay, despite all 12 subjects with a clinical diagnosis of "not TB" having received BCG, none had evidence of a detectable pulmonary PPD response. We believe this striking finding reflects the organ-specific pathway taken by vaccination-generated BCG-specific memory lymphocytes ie. trafficking through blood and homing to the skin whilst avoiding the lung [@pone.0001335-Mora1], [@pone.0001335-Hoft1]. Apart from the insight this offers for future TB vaccination strategies, we feel that these data support the use of PPD, which as a rich antigen mixture, generates higher frequency responses than RD-1 encoded antigens and therefore is likely to be beneficial in the investigation of a condition associated with immune suppression and CD4 lymphopenia in HIV-infected and HIV-uninfected individuals [@pone.0001335-Zaharatos1], [@pone.0001335-Hirsch1], [@pone.0001335-Breen2].

The sub-optimal specificity observed represents positive assays occurring in 3 subjects with a final diagnosis of quiescent or latent TB. Interestingly these individuals had co-existent conditions which traditionally make TB diagnosis difficult (2 HIV-infection, and 1 terminal malignancy) and reduce the sensitivity of the TST. Given this, it could be argued that a positive result is not such a bad thing as it alerts the clinician *not* to discount TB. That positive results are found in subjects with both quiescent or latent TB and those with active TB confounds all current immune-based assays using interferon-γ expression as the primary readout [@pone.0001335-Pai2], [@pone.0001335-Kang1]. However we have previously observed that some of the individuals with these apparent "false-positive" results may develop clearly active TB during follow up [@pone.0001335-Breen2].

When seeking to delineate between different stages of TB we believe that flow-cytometry adds more value than other immune-based tests, as it can define not only the numbers of cells producing a given cytokine but also the cell phenotype responsible in various states of TB infection. Early studies assessing the expression of both interferon-γ and surface markers of differentiation and memory status such as CD27 have hinted at the promise of such a multi-parameter flow-cytometry based approach [@pone.0001335-Streitz1].

The focus of this study has been the assessment of our induced-sputum assay in diagnosing active TB. The methodology is applicable also to studies of TB pathogenesis. To date, lung-based immunological studies have relied upon bronchoscopy. Although this usefully obtains cell-rich samples, its invasive nature makes it an unpleasant test. Sputum induction offers the possibility of longitudinal assessment of the pulmonary immune response during treatment with good subject acceptability and at greatly reduced cost. We believe that this approach opens up an important area of research which might yield markers of treatment response and even TB cure (31).

These data reveal for the first time how a lung-orientated approach combining a novel immunoassay with traditional microbiology can rapidly diagnose active TB in individuals with smear-negative disease using a single induced-sputum sample. Although a relatively small study performed in a research setting, we believe that our data warrant further work assessing the usefulness of induced-sputum as an alternative to both blood and BAL samples when investigating possible TB.
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